Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer
Cancers · 17.11.2026 · 18 (22) · 3672
DOI: 10.3390/cancers18223672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.11.2026. Verfasst von Tim Niemeier und 16 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: SLFN11 is a regulator of cellular sensitivity to DNA-damaging agents, but its role in non-small-cell lung cancer (NSCLC), particularly in the context of radiochemotherapy, remains incompletely understood. This study aimed to evaluate the association of SLFN11 with chemo- and radiosensitivity in NSCLC cell lines and to explore its potential association with clinical outcome in patients with stage III NSCLC treated with platinum-based radiochemotherapy.
Methods
SLFN11 expression was analyzed in a genetically diverse panel of NSCLC cell lines. Transient siRNA-mediated SLFN11 knockdown was performed, followed by carboplatin treatment, irradiation, and combined carboplatin–irradiation treatment. Short-term cell viability was assessed using MTS assays, while long-term survival was evaluated by clonogenic assays. Key findings were validated with a second, independent siRNA pool in two SLFN11-high cell lines, and cell cycle distribution and apoptosis were analyzed by flow cytometry. In addition, SLFN11 protein expression was assessed by immunohistochemistry in pretreatment tumor samples from a small, highly selected retrospective subgroup.
Results
SLFN11 expression varied markedly across NSCLC cell lines. SLFN11 knockdown was associated with reduced carboplatin sensitivity in selected models, with the most pronounced effects observed in SLFN11-high cell lines. This finding was reproduced with the second siRNA pool and was accompanied by attenuated carboplatin-induced S-phase accumulation and apoptosis, most consistently in HCC15 cells. In contrast, SLFN11 depletion did not consistently alter radiation response or clonogenic survival after irradiation. Combined carboplatin–irradiation treatment largely reflected the effects observed with carboplatin exposure. In the exploratory clinical subgroup, SLFN11 protein expression was not associated with progression-free survival following platinum-based radiochemotherapy.
Conclusions
These findings suggest that SLFN11 is associated with platinum-related short-term cytotoxicity and apoptosis, whereas no consistent effect on intrinsic radiosensitivity or long-term clonogenic survival was observed in the analyzed NSCLC models. The clinical analysis should be interpreted as exploratory and hypothesis-generating. Overall, the relevance of SLFN11 as a biomarker appears to be treatment-context-dependent and requires validation in larger, clinically well-defined cohorts.
Zitieren
APA
Niemeier, T., Küffer, S., Hampe, L., Scheele, N. C., Riedl, A. L., Reiß, J. J., Leu, M., Dröge, L. H., Guhlich, M., Diest, L. V., Fischer, L. A., Overbeck, T. R., Hammerstein-Equord, A. F. V., Braulke, F., Rieken, S., Bohnenberger, H., & Shafie, R. A. E. (2026). Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer. Cancers, 18(22), 3672. https://doi.org/10.3390/cancers18223672
Vancouver
Niemeier T, Küffer S, Hampe L, Scheele NC, Riedl AL, Reiß JJ, et al. Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer. Cancers. 2026;18(22):3672. doi:10.3390/cancers18223672
BibTeX
@article{Niemeier2026,
author = {Niemeier, Tim and Küffer, Stefan and Hampe, Lovis and Scheele, Niklas Christian and Riedl, Anna Luisa and Reiß, Julian Johannes and Leu, Martin and Dröge, Leif Hendrik and Guhlich, Manuel and Diest, Lisa-Antonia von and Fischer, Laura Anna and Overbeck, Tobias Raphael and Hammerstein-Equord, Alexander Freiherr von and Braulke, Friederike and Rieken, Stefan and Bohnenberger, Hanibal and Shafie, Rami Ateyah El},
title = {Evaluation of SLFN11 as a Potential Predictive Biomarker of Chemo- and Radiosensitivity in Non-Small-Cell Lung Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3672},
doi = {10.3390/cancers18223672}
}
EUVIMED